Kestra Medical Technologies Q1 revenue beats estimates, raises FY revenue outlook

Kestra Medical Technologies

14/09/2026 21:12

Overview
US wearable medical device maker's fiscal Q1 revenue grew 60%, beating analyst expectations
Adjusted EBITDA loss for fiscal Q1 slightly beat consensus
Revenue growth driven by WCD market expansion, share gains, new territories, and improved revenue cycle

Outlook
Kestra raises FY27 revenue guidance to $141 mln, up from prior $137 mln forecast
Company expects FY27 revenue growth of 48% versus FY26
Kestra sees market expansion and commercial execution driving future growth

Result Drivers
MARKET EXPANSION - Co said WCD market expansion, competitive share gains, and new sales territories drove revenue growth
IN-NETWORK PATIENTS & REVENUE CYCLE - Higher mix of in-network patients and improved revenue cycle management contributed to revenue growth
GROSS MARGIN IMPROVEMENT - Volume leverage, higher mix of in-network patients, and cost improvement programs drove gross margin expansion

Company press release: ID:nGNX5wlqWT

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$30.97 mln
$29.008 mln (7 Analysts)
Q1 Loss Per Share
 
$0.75
 
Q1 Adjusted EBITDA
Slight Beat*
-$24 mln
-$24.1 mln (5 Analysts)
Q1 Gross Profit
 
$17.5 mln
 
Q1 Income from Operations
 
-$37.66 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Kestra Medical Technologies, Ltd. is $30.00, about 31.3% above its September 11 closing price of $22.85

Reuters Recommended Reads
Sept 14 - Definium's LSD-based anxiety, depression drug scores another trial win
Sept 11 - Scholar Rock gets first FDA nod for rare muscle-wasting disease

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)